Elizabeth H.Z. Thompson - Mar 24, 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, Head of Research & Dev
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Mar 24, 2025
Transactions value $
$0
Form type
4
Date filed
3/26/2025, 07:52 PM
Previous filing
Jan 3, 2025
Next filing
Apr 2, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +91.4K $0.00 91.4K Mar 24, 2025 Common Stock 91.4K $17.23 Direct F1
transaction ACAD Restricted Stock Units Award $0 +26.9K $0.00 26.9K Mar 24, 2025 Common Stock 26.9K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning March 24, 2026.